黏膜黑色素瘤患者单用抗PD-1或联合伊匹木单抗:一项国际回顾性队列研究
这项来自25个癌症中心的国际回顾性队列研究纳入545例黏膜黑色素瘤患者,比较抗PD-1单药与联合伊匹木单抗的疗效。总体缓解率、无进展生存和总生存不因原发部位、种族或治疗方案而异;鼻口原发者联合治疗缓解率数值上更高但生存无差异。应答者中位缓解持续时间26个月,35%的初始应答者出现进展。
要点
- 545例黏膜黑色素瘤患者中,抗PD-1单药与联合伊匹木单抗的缓解率、无进展生存和总生存无显著差异。
- 鼻口原发者联合治疗缓解率40%(95%CI 29%至54%),数值上高于单药的29%(95%CI 21%至37%),但生存无差异。
- 初始应答者中35%出现进展,中位缓解持续时间26个月(95%CI 18个月至未达到)。
核心结论
- 黏膜黑色素瘤预后差;抗PD-1联合或不联合伊匹木单抗的疗效相似,且不因种族而异。
- 鼻口原发者对抗PD-1联合伊匹木单抗的缓解率数值上更高,但生存无差异;其他原发部位联合伊匹木单抗未显示优于抗PD-1单药的获益。
- 应答者中位缓解持续时间短,获得性耐药常见;其他因素包括转移部位和数量与生存相关。
研究设计与样本
- 来自澳大利亚、欧洲、美国和亚洲25个癌症中心的回顾性队列研究。
- 纳入545例组织学确诊的黏膜黑色素瘤患者,接受抗PD-1单药或联合伊匹木单抗治疗。
- 主要终点为按原发部位(鼻口、泌尿生殖、肛门直肠、其他)、种族(白人、亚洲人、其他)和治疗方案分析的缓解率、无进展生存和总生存。
- 采用单因素和多因素Cox比例风险模型分析。
主要发现
- 545例患者中331例(63%)为白人,176例(33%)为亚洲人,20例(4%)为其他种族。
- 原发部位:肛门直肠113例(21%),泌尿生殖178例(32%),鼻口206例(38%),其他45例(8%)。
- 348例(64%)接受抗PD-1单药,197例(36%)接受抗PD-1联合伊匹木单抗。
- 缓解率、无进展生存和总生存不因原发部位、种族或治疗而异;鼻口原发者联合治疗缓解率40%(95%CI 29%至54%),单药29%(95%CI 21%至37%)。
- 35%的初始应答者出现进展;中位缓解持续时间26个月(95%CI 18个月至未达到)。
关键数值与推荐
- 鼻口原发者联合治疗缓解率40%(95%CI 29%至54%),单药29%(95%CI 21%至37%)。
- 初始应答者中35%出现进展;中位缓解持续时间26个月(95%CI 18个月至未达到)。
- 与无进展生存期短相关的因素:ECOG体能状态评分≥3(P<0.01)、乳酸脱氢酶超过正常上限(P=0.01)、肺转移(P<0.01)、既往治疗≥1线(P<0.01)。
- 与总生存期短相关的因素:ECOG体能状态评分≥1(P<0.01)、乳酸脱氢酶超过正常上限(P=0.03)、肺转移(P<0.01)、既往治疗≥1线(P<0.01)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mucosal melanoma (MM) is a rare melanoma subtype with distinct biology and poor prognosis. Data on the efficacy of immune checkpoint inhibitors (ICIs) are limited. We determined the efficacy of ICIs in MM, analyzed by primary site and ethnicity/race. PATIENTS AND METHODS: A retrospective cohort study from 25 cancer centers in Australia, Europe, USA and Asia was carried out. Patients with histologically confirmed MM were treated with anti-programmed cell death protein 1 (PD-1) ± ipilimumab. Primary endpoints were response rate (RR), progression-free survival (PFS), overall survival (OS) by primary site (naso-oral, urogenital, anorectal, other), ethnicity/race (Caucasian, Asian, Other) and treatment. Univariate and multivariate Cox proportional hazards model analyses were conducted. RESULTS: In total, 545 patients were included: 331 (63%) Caucasian, 176 (33%) Asian and 20 (4%) Other. Primary sites included 113 (21%) anorectal, 178 (32%) urogenital, 206 (38%) naso-oral and 45 (8%) other. Three hundred and forty-eight (64%) patients received anti-PD-1 and 197 (36%) anti-PD-1/ipilimumab. RR, PFS and OS did not differ by primary site, ethnicity/race or treatment. RR for naso-oral was numerically higher for anti-PD-1/ipilimumab [40%, 95% confidence interval (CI) 29% to 54%] compared with anti-PD-1 (29%, 95% CI 21% to 37%). Thirty-five percent of patients who initially responded progressed. The median duration of response (mDoR) was 26 months (95% CI 18 months-not reached). Factors associated with short PFS were Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≥3 (P < 0.01), lactate dehydrogenase (LDH) more than the upper limit of normal (ULN) (P = 0.01), lung metastases (P < 0.01) and ≥1 previous treatments (P < 0.01). Factors associated with short OS were ECOG PS ≥1 (P < 0.01), LDH >ULN (P = 0.03), lung metastases (P < 0.01) and ≥1 previous treatments (P < 0.01). CONCLUSIONS: MM has poor prognosis. Treatment efficacy of anti-PD-1 ± ipilimumab was similar and did not differ by ethnicity/race. Naso-oral primaries had numerically higher response to anti-PD-1/ipilimumab, without difference in survival. The addition of ipilimumab did not show greater benefit over anti-PD-1 for other primary sites. In responders, mDoR was short and acquired resistance was common. Other factors, including site and number of metastases, were associated with survival.
引用
- Dimitriou F, Namikawa K, Reijers ILM, et al. Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study. Ann Oncol. 2022. PMID: 35716907. doi:10.1016/j.annonc.2022.06.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。